Go To Global Site
Welcome to UCB in the United States

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

26

The IP PACT: Our Commitment to Putting Patients at the Heart of Our Approach to IP

UCB is proud to be one of 26 members launching the IP PACT and we invite you to learn more about the commitments we are making to ensure our approach to IP delivers value for society, patients, and UCB.

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

Apr

23

UCB Showcases Approach to Creating Patient Value in Immuno-Dermatology

At UCB, we have come to develop a deep understanding of the patient experience and the unmet needs of people living with immuno-dermatological conditions. As we join for the American Academy of Dermatology VMX 2021 Conference, read from Rhonda Peebles, our Head of U.S. Dermatology, on UCB’s approach to creating value for patients.

Apr

22

Earth Day: Supporting the Health of the Planet

Sustainability is our business approach at UCB. Our goal is to contribute to the transition toward a low-carbon and green economy to protect the planet by developing and producing medicines for people with severe diseases in the most environmentally sustainable way possible. This means reducing our carbon footprint, water consumption, and waste production across the company. This Earth Day, we are highlighting how we’ve progressed in our goal to reduce our local and global environmental impact by 2030, despite the unprecedented events of 2020.

Apr

19

Reimagining UCB’s U.S. Headquarters to Deliver More Value for Employees, the Healthcare Ecosystem, and the Greater Atlanta Community

At UCB, we know that fostering a strong employee culture and a rewarding work environment is critical to continuing to innovate for patients living with severe immunological and neurological conditions. Over the past year, the future of where and how we work and collaborate has been put to the test by COVID-19. Read more from Head of U.S. Corporate Affairs, Patty Fritz, on how UCB is reimagining the workplace at our U.S. Headquarters in Atlanta, Georgia.

Apr

16

Together Towards Recovery: How a Year of Distance Has Brought Us Closer to the Needs of Patients

With more than 20 years of experience in caring for people living with epilepsy, our goal has always been to know and understand the day-to-day experiences of people living with the disease better than anyone. Over the past year this has been especially true, and the challenges we’ve faced have reinvigorated our commitment to the overall emotional and physical well-being of patients. Read more from UCB’s Head of U.S. Neurology, Mike Davis, about how UCB is finding new ways to better connect with patients and improve their day-to-day experience.

Apr

16

UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Apr

05

Celebrating Warriors with Parkinson’s Disease

Today, across the globe, people are being impacted by COVID-19, causing not only illness, but also uncertainty and fear. With April being Parkinson’s Awareness month, we're sharing the inspirational stories of PD Warriors who are breaking barriers despite their diagnosis to spread a little positivity during this challenging time. These warriors recently shared their stories with More Than Motion, UCB’s community dedicated to raising awareness of the realities of living with Parkinson's disease (PD), and we're honored to feature them this month.